Boehringer Ingelheim
Coverage of Boehringer Ingelheim in the Nexus archive.
- STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
Boehringer Ingelheim's obesity drug survodutide showed 13% weight loss in a Phase 3 trial, lower than Novo Nordisk's Wegovy and Eli Lilly's Zepbound. While the drug reduced liver fat by 63%, it appears less efficacious and tolerable compared to existing treatments.
- STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more
Eli Lilly is reducing its $2.67 billion investment in Germany's weight-loss syringe production due to new cost-cutting laws, and Boehringer Ingelheim is cutting $1 billion in German investments amid sector uncertainty. U.S. FDA Acting Commissioner Kyle Diamantas is engaging rare disease groups to address concerns raised by his predecessor's policies.
- STAT+: Supreme Court rejects challenge to Medicare drug price negotiation
The Supreme Court rejected a challenge to the Medicare drug price negotiation program, declining to take up lawsuits from several pharmaceutical companies. The decision is a blow to the brand drug industry's legal campaign against the program. The court did not provide a reason for its decision.